Malin Corporation

Malin Corporation EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Malin Corporation (MLC.IR) as of Oct 10, 2026 is -1.26 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -3.34 % — a change of -62.35% (higher).

EBIT/Assets

-1.26 %

YoY

-62.35%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Malin Corporation is 2024 -1.26 % . Operating Income to Assets Ratio (EBIT/Assets) of Malin Corporation was 2023 -3.34 % . It decreases by -62.35% higher compared to the previous year.

The Malin Corporation EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2017
-14.71 EUR
Jan 1, 2018
-16.75 EUR
Jan 1, 2019
-1.25 EUR
Jan 1, 2020
25.42 EUR
Jan 1, 2021
-1.14 EUR
Jan 1, 2022
-0.24 EUR
Jan 1, 2023
-3.34 EUR
Jan 1, 2024
-1.26 EUR
The Malin Corporation EBIT/Assets history
YEAREBIT/AssetsYoY
-1.26 %-62.35%
-3.34 %+1,275.66%
-0.24 %-78.66%
-1.14 %-104.48%
25.42 %-2,131.96%
-1.25 %-92.53%
-16.75 %+13.92%
-14.71 %-27.02%
-20.15 %+216.64%
-6.36 %—
Access this data via the Eulerpool API

Malin Corporation Stock analysis

What does Malin Corporation do? Malin Corporation PLC is an Irish company that was founded in 2014. The company is a subsidiary of Elan, a company specialized in pharmaceutical development. Malin has focused its business model on identifying, supporting, and scaling startup companies. The company supports and invests in startups in the biopharmaceutical industry that focus on new and innovative therapies. Malin offers help and advice to its portfolio companies in product development and business organization. The company has invested in various areas of the biopharmaceutical industry. For example, it has supported YumaTherapeutics, a company focused on the discovery and development of novel therapeutics for infectious diseases. Malin has also provided financial support to Seres Therapeutics, which has built a pipeline of therapeutics targeting the microbiome, the collection of microorganisms living in the gut. Malin has invested in Inivata, a company specialized in the development of cancer diagnostics. Furthermore, Malin has various other companies in its investment pipeline that deal with a variety of therapeutic possibilities. This includes therapies for genetic diseases and inherited metabolic disorders, as well as applications of gene therapy and immunotherapy. Malin Corporation PLC has also developed its own products and partnerships. One of these partnerships is with Novaerus, another Irish company specialized in the development of air purification systems. Novaerus systems use a plasma-based ion system to destroy bacteria, viruses, and fungi in the air, thus preventing infections. Malin is also involved in research collaborations. One collaboration is with University College Dublin, where Malin provides financial support for research on biopharmaceutical processes. The history of Malin Corporation PLC is characterized by a strong commitment to supporting innovative companies in the biopharmaceutical industry. The company aims to promote the growth and development of startups, offering not only financial support but also advice and expertise. Malin has diversified its investments in various areas of the biopharmaceutical industry and focuses on promoting products that improve people's health and well-being. The company has also developed its own products and partnerships to bring new technologies and therapies to the market. Overall, Malin Corporation PLC is a company specialized in supporting and promoting startups in the biopharmaceutical industry. The company is committed to developing products and therapies that have the potential to improve and prolong people's lives. Malin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Malin Corporation stock

Operating Income to Assets Ratio (EBIT/Assets) of Malin Corporation is -1.26 % in 2024.

Operating Income to Assets Ratio (EBIT/Assets) of Malin Corporation changed from -3.34 % to -1.26 %, representing a -62.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Malin Corporation since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Malin Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — Malin Corporation

All Key Metrics — Malin Corporation